[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Henan University of Traditional Chinese Medicine\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":566},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,23,0,[8,45,75,102,128,149,176,199,223,249,273,292,315,341,365,386,409,431,451,475,499,520,541],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100643271","evaluation-of-clinical-effect-of-acupuncture-on-acute-exacerbation-of-bronchial-asthma-100643271",false,"NCT07632352","Evaluation of Clinical Effect of Acupuncture on Acute Exacerbation of Bronchial Asthma","Evaluation of Clinical Effect of Acupuncture on Acute Exacerbation of Bronchial Asthma Based on Biological Holography Theory","Inclusion Criteria:\n\n1. Patients meeting the Western medicine diagnostic criteria for acute exacerbation of bronchial asthma\n2. Aged ≥ 18 years old\n3. Voluntarily receive treatment and sign the informed consent form\n\nExclusion Criteria:\n\n1. Those who fail to meet the inclusion criteria\n2. Patients suffering from other severe systemic diseases such as diseases of the circulatory system, hematological system and nervous system\n3. Pregnant or lactating women\n4. Subjects enrolled but not treated per the study protocol\n5. Patients who have participated in other clinical trials of medicinal products within 3 months\n6. Other circumstances deemed ineligible for enrollment by researchers","ALL","18 Years",{"count":19,"type":20},72,"ESTIMATED","INTERVENTIONAL",[23],"NA","Based on the bioholographic theory, this study preliminarily explores the clinical efficacy of hand acupuncture in treating acute exacerbation of bronchial asthma and evaluates its immediate anti-asthmatic effect, so as to provide a new therapeutic strategy for the clinical management of bronchial asthma.",[26],"Bronchial Asthma",[28,29,30,31],"bronchial asthma","acute exacerbation","Biological holography theory","Acupuncture","RECRUITING","2026-06-02",{"date":35,"type":36},"2026-06-08","ACTUAL",{"date":38,"type":36},"2025-04-15",{"date":40,"type":20},"2027-01-01",{"name":42,"class":43},"Henan University of Traditional Chinese Medicine","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},"100620043","modified-shenling-baizhu-powder-for-allergic-asthma-with-spleen-deficiency-and-dampness-accumulation-syndrome-100620043","NCT07352488","Modified Shenling Baizhu Powder for Allergic Asthma With Spleen Deficiency and Dampness Accumulation Syndrome","Effect of Modified Shenling Baizhu Powder on Allergic Asthma With Spleen Deficiency and Dampness Accumulation Syndrome: A Multicenter, Randomized Controlled Trial","mSLBZP-Asthma","Inclusion Criteria:\n\n* Patients who are persistent allergic asthma.\n* Patients who meet the diagnostic criteria for the spleen deficiency and dampness accumulation syndrome.\n* Patients who are aged between 18 and 80 years.\n* Patients who voluntarily accept the treatment and sign the informed consent form.\n\nExclusion Criteria:\n\n* Patients who have chronic obstructive pulmonary disease, interstitial lung disease, bronchiectasis, allergic bronchopulmonary aspergillosis, eosinophilic granulomatosis with polyangiitis , active pulmonary tuberculosis, or pulmonary embolism, etc.\n* Patients who have severe cardiovascular or cerebrovascular diseases.\n* Patients who have severe liver or kidney diseases.\n* Patients who have a history of tumor.\n* Patients who have cognitive impairment or psychiatric disorders.\n* Patients who are pregnant or breastfeeding.\n* Patients who are allergic to medication(s) used.\n* Patients who participated in another clinical trial within one month prior to enrollment.","80 Years",{"count":55,"type":20},400,[23],"Allergic asthma is a common allergic disease characterized by a protracted disease course and recurrent episodes, which severely impairs patients' physical and mental health. There is a paucity of high-quality clinical evidence in the treatment of allergic asthma with traditional Chinese medicine (TCM). This study will enroll patients who are persistent allergic asthma with spleen deficiency and dampness accumulation syndrome. A multicenter, randomized, double-blind, placebo-controlled trial design is adopted. The experimental group will receive Modified Shenling Baizhu Powder in addition to Budesonide and Formoterol Fumarate Powder for Inhalation, while the control group will receive a placebo in addition to the same inhalation therapy. Both groups will undergo an 8 week of treatment followed by a 12 week of follow-up. The primary outcome is Asthma Control Test scores, and the secondary outcomes include acute exacerbations, Asthma Control Questionnaire scores, Asthma Quality of Life Questionnaire scores, pulmonary function, airway inflammatory markers, clinical symptom scores, serum inflammatory markers, immune markers, and use of controller medications.",[59],"Allergic Asthma",[61,62,63,64],"Allergic asthma","Modified Shenling Baizhu Powder","Spleen Deficiency and Dampness Accumulation Syndrome","Randomized controlled trial","NOT_YET_RECRUITING","2026-01-11",{"date":68,"type":36},"2026-01-20",{"date":70,"type":20},"2026-01-15",{"date":72,"type":20},"2028-03-31",{"name":42,"class":43},3,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":84,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":4},"100608837","a-study-on-integrated-chinese-and-western-medicine-for-severe-pneumonia-caused-by-multidrug-resistant-gram-negative-bacterial-infections-100608837","NCT07206745","A Study on Integrated Chinese and Western Medicine for Severe Pneumonia Caused by Multidrug-Resistant Gram-Negative Bacterial Infections","Efficacy Evaluation of Integrated Traditional Chinese and Western Medicine in the Treatment of Severe Pneumonia Caused by Multidrug-Resistant Gram-Negative Bacterial Infections: A Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n* Meeting the diagnostic criteria for severe pneumonia, aged ≥18 years and \\\u003C80 years;\n* Microbiological culture confirming Gram-negative bacterial infection resistant to three or more classes of antibiotics, such as extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, carbapenem-resistant Acinetobacter baumannii (CRAB), and multidrug-resistant Pseudomonas aeruginosa (MDR-PA);\n* Written informed consent obtained from the patient or their legal representative.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women;\n* Patients with impaired consciousness, dementia, psychiatric disorders, or other conditions that preclude effective communication and cooperation;\n* Patients with aspiration pneumonia, fungal pneumonia, viral pneumonia, pulmonary tuberculosis, or HIV-associated Pneumocystis jirovecii pneumonia;\n* Patients with severe hepatic or renal insufficiency, such as liver cirrhosis with Child-Pugh score of 10-15, or estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73 m²;\n* Patients with hematologic malignancies, solid organ transplantation, or congenital\u002Facquired diseases leading to immunodeficiency;\n* Patients with multidrug-resistant bacterial infections outside the lung (e.g., urinary tract, abdominal cavity, bloodstream);\n* Patients with severe cardiac dysfunction (NYHA class IV), malignant arrhythmias, or other hemodynamically unstable conditions;\n* Patients who have already received antimicrobial therapy for more than one week;\n* Patients who have participated in another drug clinical trial within one month prior to enrollment;\n* Patients with known allergy to the investigational drug.",{"count":83,"type":20},152,[23],"This study aims to evaluate the clinical efficacy of a traditional Chinese medicine formula granule (Feireqing Granules) in the treatment of severe pneumonia caused by multidrug-resistant Gram-negative bacterial infections (MDR-GNB severe pneumonia), to establish a therapeutic regimen, and to generate high-quality clinical evidence.",[87],"Severe Pneumonia Caused by Multidrug-resistant Gram-negative Bacterial Infection",[89,90,91,92,93],"Severe pneumonia","multidrug-resistant Gram-negative bacterial infection","traditional Chinese medicine","randomized controlled trial","Fei Re Qing Granules","2025-09-26",{"date":96,"type":36},"2025-10-03",{"date":98,"type":20},"2025-10-01",{"date":100,"type":20},"2027-12-31",{"name":42,"class":43},{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":44},"100606656","disease-syndrome-characteristics-of-ipf-100606656","NCT07178392","Disease-syndrome Characteristics of IPF","Research on the Disease-syndrome Characteristics of Idiopathic Pulmonary Fibrosis","Inclusion Criteria:\n\n1. Patients diagnosed with IPF;\n2. Age ≥ 18 years old;\n3. Voluntarily participate in this study and sign an informed consent form.\n\nExclusion Criteria:\n\n1. Patients with confusion, dementia, consciousness disorders, and various mental illnesses;\n2. Those who are unable to take care of themselves and have been bedridden for a long time.",{"count":110,"type":20},2864,"OBSERVATIONAL","This study, based on previous registration records, aims to explore the syndrome patterns, disease characteristics, and their interrelationships of IPF at different stages, grades, and in its natural course, thus providing a multidimensional interpretation of the syndrome patterns and characteristics of IPF.",[114],"Idiopathic Pulmonary Fibrosis (IPF)",[116,117,118,119],"Idiopathic Pulmonary Fibrosis","TCM","Epidemiological investigation","characteristics","2025-09-10",{"date":122,"type":36},"2025-09-17",{"date":124,"type":20},"2025-09-15",{"date":126,"type":20},"2028-11-30",{"name":42,"class":43},{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":16,"minAge":135,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":138,"conditions":139,"keywords":140,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":148,"locationsCount":44},"100605465","idiopathic-pulmonary-fibrosis-cohort-of-tcm-100605465","NCT07162870","Idiopathic Pulmonary Fibrosis Cohort of TCM","Idiopathic Pulmonary Fibrosis Cohort Studies of Chinese Medicine","Inclusion Criteria:\n\n1. Patients diagnosed with IPF;\n2. Age ≥ 40 years old;\n3. Voluntary participation in this study,And sign the informed consent form.\n\nExclusion Criteria:\n\n1. Patients with confusion, dementia, consciousness disorders, and various mental illnesses;\n2. Patients who are unable to take care of themselves and have been bedridden for a long time.","40 Years",{"count":137,"type":20},1000,"This study, based on past registration records, evaluates the clinical efficacy of traditional Chinese medicine in treating IPF in the real world, identifies advantageous populations and clinical targets, and provides references for precision traditional Chinese medicine treatment.",[114],[116,117,141],"Cohort","2025-08-31",{"date":144,"type":36},"2025-09-09",{"date":146,"type":20},"2025-09-05",{"date":126,"type":20},{"name":42,"class":43},{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":156,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":157,"targetDuration":4,"studyType":21,"phases":159,"briefSummary":160,"conditions":161,"keywords":163,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":44},"100603015","study-on-the-mechanism-of-yifei-moxibustion-improving-immune-function-in-copd-based-on-plasma-exosome-mirnas-100603015","NCT07131020","Study on the Mechanism of Yifei Moxibustion Improving Immune Function in COPD Based on Plasma Exosome miRNAs","Study on the Mechanism of Yifei Moxibustion in Enhancing Immune Function in Chronic Obstructive Pulmonary Disease Based on Plasma Exosomal miRNAs","Inclusion Criteria:\n\n* Patients who meet the diagnostic criteria for stable chronic obstructive pulmonary disease;\n\n  * Patients who meet the TCM diagnostic criteria for lung qi deficiency, lung-spleen qi deficiency, and lung-kidney qi deficiency; ③ Aged 18 to 80 years old; ④ Voluntarily signed the informed consent form.\n\nExclusion Criteria:\n\n* Pregnant and lactating women;\n\n  * Patients with cognitive impairment, confusion, dementia, or various mental disorders;\n\n    * Patients with unstable angina pectoris or acute myocardial infarction;\n\n      * Patients with a history of syncope after exercise or bone and joint diseases that affect exercise; ⑤ Patients with pneumothorax, pleural effusion, pulmonary embolism, or tumors;\n\n        * Patients known to be allergic to the ingredients of the moxibustion powder.",true,{"count":158,"type":20},120,[23],"This study adopted a randomized controlled design, enrolling 90 patients and 30 healthy volunteers. The patients were randomly divided into the Yifei Moxibustion group, the conventional Western medicine treatment group, and the TCM syndrome differentiation treatment group, and were treated for 3 months. Peripheral venous blood was collected from both the healthy volunteers and the patients to observe indicators such as T cell subsets and immunoglobulins, to evaluate the effect of Yifei Moxibustion on improving immune function. The regulation of target genes by exosomes and potential action targets and molecular mechanisms were preliminarily verified through techniques such as nanoparticle tracking technology and flow cytometry.",[162],"Stable COPD Patients",[164,165,166,167],"COPD","Yifei moxibustion","miR-125b","macrophage polarization","2025-08-18",{"date":170,"type":36},"2025-08-19",{"date":172,"type":36},"2024-05-11",{"date":174,"type":20},"2025-09",{"name":42,"class":43},{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":16,"minAge":135,"maxAge":183,"enrollmentInfo":184,"targetDuration":4,"studyType":21,"phases":186,"briefSummary":187,"conditions":188,"keywords":190,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":198,"locationsCount":44},"100586387","jin-shui-huan-xian-formula-for-retarding-the-decline-of-pulmonary-function-in-ipf-100586387","NCT06914713","Jin-shui Huan-xian Formula for Retarding the Decline of Pulmonary Function in IPF","Efficacy Evaluation of Jin-shui Huan-xian Formula in Retarding the Decline of Pulmonary Function in IPF","Inclusion Criteria:\n\n1. Patients who meet the diagnostic criteria for IPF.\n2. Pulmonary function: The percentage of forced vital capacity (FVC) to the predicted value is ≥ 50%; and the percentage of the diffusing capacity of the lung for carbon monoxide (DLCO) to the predicted value is ≥ 30%.\n3. Patients who meet the syndrome - differentiation criteria for lung - qi deficiency syndrome, lung - and - kidney qi deficiency syndrome, etc.\n4. Aged between 40 and 85 years old.\n5. Patients who voluntarily accept the treatment and sign the informed consent\n\nExclusion Criteria:\n\n1. Patients in the acute exacerbation phase of IPF.\n2. Patients complicated with other pulmonary diseases such as chronic obstructive pulmonary disease (COPD), lung cancer, active pulmonary tuberculosis, bronchiectasis, and pulmonary embolism.\n3. Patients with severe joint, peripheral nerve, and peripheral vascular diseases that affect limb movement and who are bed - ridden for a long time and cannot complete the six - minute walk test.\n4. Patients complicated with severe cardiovascular and cerebrovascular diseases (malignant arrhythmia, unstable angina pectoris, acute myocardial infarction, heart function grade 3 or above, stroke, cerebral hemorrhage, etc.).\n5. Patients complicated with liver diseases such as cirrhosis or secondary portal hypertension, bleeding caused by esophageal and gastric varices, patients with kidney diseases requiring dialysis or kidney transplantation, or patients with abnormal liver and kidney functions (ALT, AST, and BUN are 1.5 times higher than the upper limit of the normal range, and blood Cr is higher than the upper limit of the normal range).\n6. Patients with unclear consciousness, various mental illnesses, etc., who cannot communicate normally.\n7. Pregnant or lactating women and patients with a recent plan for pregnancy.\n8. Patients who have participated in other clinical trials within 1 month before enrollment.\n9. Patients known to be allergic to any of the test medications and their components.","85 Years",{"count":185,"type":20},384,[23],"This study is to evaluate the clinical efficacy and safety of Jin-shui Huan-xian Formula in retarding the decline of pulmonary function in IPF, generate high - quality clinical evidence, and establish a treatment plan of Jin-shui Huan-xian Formula for retarding the decline of pulmonary function in Idiopathic Pulmonary Fibrosis（IPF）",[189],"Idiopathic Pulmonary Fibrosis(IPF)",[116,91,92,191],"pulmonary function","2025-07-31",{"date":194,"type":36},"2025-08-05",{"date":196,"type":20},"2025-08-01",{"date":126,"type":20},{"name":42,"class":43},{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":16,"minAge":135,"maxAge":53,"enrollmentInfo":206,"targetDuration":4,"studyType":21,"phases":208,"briefSummary":209,"conditions":210,"keywords":212,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":44},"100590124","clinical-study-on-improving-exercise-capacity-in-chronic-obstructive-pulmonary-disease-through-smart-iot-remote-home-breathing-guidance-100590124","NCT06963333","Clinical Study on Improving Exercise Capacity in Chronic Obstructive Pulmonary Disease Through Smart IoT-Remote Home Breathing Guidance","Clinical Study on Improving Exercise Capacity in Chronic Obstructive Pulmonary Disease Through Smart IoT-Remote Home Breathing Guidance: A Multicenter, Randomized, Controlled Clinical Trial","Inclusion Criteria:\n\n* Patients with COPD in stable stage\n* Patients with grade 2 to 4 lung function\n* Age 40\\~80 years old\n* Be able to use smart phones, computers and other devices independently or with the help of family members during home training\n* Volunteer for treatment and sign an informed consent form\n\nExclusion Criteria:\n\n* Pregnant or lactating women and patients with recent pregnancy plans\n* Delirious, dementia, all kinds of mental illness\n* Tumor patients who have undergone resection, radiation, and chemotherapy within 5 years\n* Patients with severe osteoarthropathy or osteoporosis, unstable fractures\n* Patients with severe visual impairment that cannot be improved or who have epilepsy or vertigo and cannot use VR devices\n* Patients with progressive neuromuscular disease\n* Patients with pulmonary abscess, pulmonary interstitial fibrosis, active pulmonary tuberculosis, bronchiectasis, pulmonary embolism and other pulmonary diseases\n* Patients with severe cardiovascular and cerebrovascular diseases (malignant arrhythmia, unstable angina pectoris, acute myocardial infarction, grade 3 or above cardiac function, stroke, cerebral hemorrhage, etc.)\n* Patients with severe liver disease (cirrhosis, portal hypertension and bleeding caused by esophageal and gastric varices, etc.) and severe kidney disease (dialysis, kidney transplantation, etc.)\n* Participants who were participating in other clinical trials within 1 month prior to enrollment\n* People who stay in bed for a long time for various reasons",{"count":207,"type":20},548,[23],"This study aims to evaluate the clinical efficacy of breath-guided improvement of COPD exercise ability, establish a breath-guided rehabilitation program of intelligent iot and remote home, improve COPD exercise ability, reduce acute exacerbation, and form high-quality clinical evidence.",[211],"Chronic Obstructive Pulmonary Disease",[213,214,92],"Stable stage of chronic obstructive pulmonary disease","Tele-home rehabilitation","2025-05-06",{"date":217,"type":36},"2025-05-09",{"date":219,"type":20},"2025-06-15",{"date":221,"type":20},"2028-07-31",{"name":42,"class":43},{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":230,"targetDuration":232,"studyType":111,"phases":4,"briefSummary":233,"conditions":234,"keywords":236,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":44},"100586667","the-severity-assessment-model-for-aecopd-with-combination-of-disease-and-syndrome-100586667","NCT06918353","The Severity Assessment Model for AECOPD With Combination of Disease and Syndrome","Construction and Evaluation of the Severity Assessment Model for AECOPD With Combination of Disease and Syndrome Based on Machine Learning","Inclusion Criteria:\n\n* Meets AECOPD diagnostic criteria.\n* Voluntarily participate in the research and sign the consent form\n\nExclusion Criteria:\n\n* Individuals with severe mental disorders and cognitive impairments who are unable to communicate normally",{"count":231,"type":20},1500,"1 Day","The establishment of the AECOPD severity assessment model can quickly and accurately evaluate the condition, which is of great significance for standardizing diagnosis and treatment, improving efficacy, and improving prognosis. At the same time, it can provide ideas and methods for the research of disease assessment models in related fields.",[235],"Acute Exacerbation of Chronic Obstructive Pulmonary Disease",[235,237,238,239,240],"Severity Assessment Model","Combination of Disease and Syndrome","Classification and Regression Trees","Artificial Neural Network","2025-04-09",{"date":243,"type":36},"2025-04-11",{"date":245,"type":20},"2025-04-01",{"date":247,"type":20},"2028-12-31",{"name":42,"class":43},{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":256,"targetDuration":4,"studyType":21,"phases":258,"briefSummary":259,"conditions":260,"keywords":263,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":4},"100582915","study-on-acupuncture-treatment-of-chronic-airway-diseasesasthma-and-chronic-obstructive-pulmonary-disease-100582915","NCT06869525","Study on Acupuncture Treatment of Chronic Airway Diseases(Asthma and Chronic Obstructive Pulmonary Disease)","Study on the Efficacy and Mechanism of Acupuncture in the Acute Stage of Chronic Airway Diseases (Asthma and Chronic Obstructive Pulmonary Disease)","Inclusion Criteria:\n\n* Meets the diagnostic criteria for acute attack of asthma\u002FAECOPD;\n* Age range from18 years to 80 years(asthma) and 40 yesrs to 80 years(COPD);\n* The investigators agreed to participate in this clinical study by voluntarily signing an informed consent form.\n\nExclusion Criteria:\n\n* Patients with combined pulmonary abscess, pulmonary interstitial fibrosis, active pulmonary tuberculosis, bronchiectasis and other pulmonary diseases;\n* Patients with severe cardiovascular and cerebrovascular diseases (such as malignant arrhythmia, unstable angina pectoris, acute myocardial infarction, grade 3 or above cardiac function, stroke, cerebral hemorrhage, etc.);\n* Patients with severe liver diseases (such as liver cirrhosis, portal hypertension and bleeding caused by esophageal and gastric fundus varices) and severe kidney diseases (such as dialysis, kidney transplantation, etc.);\n* Patients with impaired consciousness or various mental disorders who are unable to communicate normally;\n* Pregnant and lactating women;\n* Those who are currently participating in other clinical trials within 1 month before enrollment;\n* Patients with contraindications to acupuncture (such as severe allergic or infectious skin diseases);",{"count":257,"type":20},576,[23],"For patients in the acute phase of chronic airway diseases, on the basis of guideline-directed treatment, the experimental group was given acupuncture treatment, while the control group was given sham acupuncture treatment. The treatment lasted for one week, followed by a 13-week follow-up. For asthma and COPD, PEF and CAT were respectively used as the primary outcome measures to evaluate the clinical efficacy and safety of acupuncture. Based on the improvement of the primary outcome measures, the advantageous population was identified. The mechanism by which acupuncture reduces airway mucus hypersecretion was preliminarily explained.",[261,262],"COPD Exacerbation Acute","Asthma Acute",[261,262,31,264],"Randomized Controlled Trial","2025-03-05",{"date":267,"type":36},"2025-03-11",{"date":269,"type":20},"2025-03",{"date":271,"type":20},"2027-12",{"name":42,"class":43},{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":183,"enrollmentInfo":279,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":281,"conditions":282,"keywords":284,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":290,"leadSponsor":291,"locationsCount":4},"100532992","respiratory-disease-cohort-studies-of-chinese-medicine-for-pneumonia-research-pneumonia-100532992","NCT06220019","REspiratory diSEAse cohoRt Studies of CHinese Medicine for Pneumonia (RESEARCH-Pneumonia)","Selection Criteria:\n\n* Hospitalized patients with a confirmed diagnosis of pneumonia (HAP, CAP).\n* Age ≥18 years.\n* Signed informed consent form.\n\nExclusion Criteria:\n\n* Patients with confusion, consciousness disorders, dementia, and various mental illnesses;\n* Patients with altered mental status, dementia, consciousness disorders, or various psychiatric conditions;\n* Those who are completely unable to care for themselves or are bedridden long-term; and those currently participating in other clinical drug trials.\n* Known to be allergic to treatment drugs.",{"count":280,"type":20},5000,"The purpose of this study is to evaluate the clinical efficacy and safety of dialectical treatment in the patients with pneumonia after discharge in a prospective cohort study: one is the Traditional Chinese Medicine (TCM) cohort, which has been evaluated and has certain effects; The other is a non traditional Chinese medicine queue.",[283],"Pneumonia",[283,285,141],"Chinese Medicine","2024-12-26",{"date":288,"type":36},"2024-12-30",{"date":286,"type":20},{"date":271,"type":20},{"name":42,"class":43},{"id":293,"slug":294,"hasResults":11,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":4,"eligibilityCriteria":298,"healthyVolunteers":11,"sex":16,"minAge":299,"maxAge":53,"enrollmentInfo":300,"targetDuration":4,"studyType":21,"phases":301,"briefSummary":302,"conditions":303,"keywords":305,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":4},"100573518","clinical-trial-of-fei-re-qing-granules-in-the-treatment-of-elderly-community-acquired-pneumonia-100573518","NCT06747325","Clinical Trial of Fei Re Qing Granules in the Treatment of Elderly Community-Acquired Pneumonia","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Fei Re Qing Granules in the Treatment of Elderly Community-Acquired Pneumonia","Inclusion Criteria:\n\n* Inpatients diagnosed with community-acquired pneumonia (CAP) according to the diagnostic criteria.\n* Diagnosed with Phlegm-Heat Obstructing the Lungs syndrome based on Traditional Chinese Medicine (TCM).\n* Aged ≥65 and ≤80 years, regardless of gender.\n* Onset of illness within 72 hours.\n* Clinical symptoms must include at least two of the following four primary。symptoms: cough, sputum production, dyspnea, and pleuritic chest pain.\n* Voluntary participation and signed informed consent.\n\nExclusion Criteria:\n\n* Patients with altered mental status, consciousness disorders, dementia, or psychiatric disorders.\n* Patients requiring invasive mechanical ventilation or endotracheal intubation.\n* Patients with conditions such as pleural effusion, bronchiectasis, active pulmonary tuberculosis, pulmonary abscess, lung cancer, asthma, or chronic obstructive pulmonary disease (COPD).\n* Patients with neuromuscular diseases or those bedridden for long periods, posing a risk of aspiration.\n* Patients with cancer, severe cardiovascular diseases (acute myocardial infarction, heart failure stage III or above), or severe liver and kidney diseases (e.g., cirrhosis, portal hypertension with variceal bleeding, dialysis, or kidney transplantation).\n* Patients participating in other drug clinical trials or known to be allergic to the study medication.","65 Years",{"count":158,"type":20},[23],"This study aims to evaluate the clinical efficacy of traditional Chinese medicine formula granules (Fei Re Qing Granules) in the treatment of elderly community-acquired pneumonia, establish a treatment protocol, and obtain high-level clinical evidence.",[304],"Community-Acquired Pneumonia (CAP)",[306,91,92,93],"elderly community-acquired pneumonia (CAP)","2024-12-18",{"date":309,"type":36},"2024-12-24",{"date":311,"type":20},"2025-01-01",{"date":313,"type":20},"2025-06-01",{"name":42,"class":43},{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":322,"targetDuration":4,"studyType":21,"phases":324,"briefSummary":325,"conditions":326,"keywords":329,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":44},"100569250","clinical-study-on-the-treatment-of-chronic-airway-diseases-asthma-chronic-obstructive-pulmonary-disease-with-shu-fei-tie-100569250","NCT06691802","Clinical Study on the Treatment of Chronic Airway Diseases (Asthma, Chronic Obstructive Pulmonary Disease) with Shu Fei Tie","Clinical Study on Reducing Recurrent Attacks of Chronic Airway Diseases (asthma, Chronic Obstructive Pulmonary Disease) with Shu Fei Tie Based on \"winter Disease Being Cared in Summer\"","Inclusion Criteria:\n\n* Meets the diagnostic criteria for asthma\u002FCOPD(Group E in the GOLD classification); ② Age range from18 years to 80 years(asthma) and 40 yesrs to 80 years(COPD);\n\n  * The investigators agreed to participate in this clinical study by voluntarily signing an informed consent form.\n\nExclusion Criteria:\n\n* Patients with other pulmonary diseases (lung abscess, pulmonary interstitial fibrosis, active pulmonary tuberculosis, bronchiectasis，etc);\n\n  * Patients with severe cardiovascular and cerebrovascular diseases (malignant arrhythmia, unstable angina, acute myocardial infarction, heart grade 3 or above, stroke, cerebral hemorrhage, etc.);\n\n    * Patients with severe liver diseases (liver cirrhosis, portal hypertension, and caused by esophageal and gastric varices) and severe kidney diseases (dialysis, kidney transplantation, etc.);\n\n      * Patients with impaired consciousness or various illnesses who cannot communicate normally; ⑤Pregnant and lactating women; ⑥Patients who are participating in other clinical trials within one month prior to enrollment; ⑦Patients who have received acupuncture or other traditional Chinese medicine external treatments within the past year; ⑧ Patients who are allergic to external patches",{"count":323,"type":20},2312,[23],"Conduct a multi-center, large-sample, randomized controlled clinical study of \"winter disease being cared in summer\" with Shu Fei Tie prevent recurrence of Asthma and COPD, scientifically evaluate the clinical efficacy and safety of Shu Fei Tie in reducing the recurrence of chronic airway diseases, identify target population, clarify the mechanism of efficacy, and establish a prevention and treatment technology plan for Shu Fei Tie to reduce the recurrence of chronic airway diseases.",[327,328],"Chronic Obstructive Pulmoriary Disease (COPD)","Asthma",[330,328,331,332,264],"Chronic Obstructive Pulmoriary Disease","Shu Fei Tie","Winter disease being cared in summer","2024-11-14",{"date":335,"type":36},"2024-11-15",{"date":337,"type":20},"2024-12",{"date":339,"type":20},"2028-07",{"name":42,"class":43},{"id":342,"slug":343,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":4,"eligibilityCriteria":347,"healthyVolunteers":11,"sex":16,"minAge":348,"maxAge":53,"enrollmentInfo":349,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":351,"conditions":352,"keywords":355,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":364,"locationsCount":4},"100568752","research-on-the-characteristics-of-chronic-airway-diseases-asthma-copd-100568752","NCT06685315","Research on the Characteristics of Chronic Airway Diseases (asthma, COPD)","Research on the Syndrome Characteristics of Chronic Airway Diseases (asthma, Chronic Obstructive Pulmonary Disease) Based on Intelligent Algorithm Fusion of Phenotype Omics","Inclusion Criteria:\n\n* Meets the diagnostic criteria for asthma or COPD.\n* Age of athma range from 12 years to 80 years.Age of COPD range from 18 years to 80 years.\n* The investigators agreed to participate in this clinical study by voluntarily signing an informed consent form.\n\nExclusion Criteria:\n\n* Patients with respiratory diseases such as interstitial lung disease, lung malignant tumor, lung infectious diseases, pneumothorax, pleural effusion, etc., which affect the syndrome differentiation.\n* Patients with combining severe cardiovascular and cerebrovascular diseases, severe liver and kidney diseases, severe hematological malignancies, etc., affecting syndrome differentiation.\n* Patients with delirium, dementia, various mental illnesses.","12 Years",{"count":350,"type":20},10545,"This study will to investigate the correlation between the characteristics of the population with chronic airway diseases (asthma, chronic obstructive pulmonary disease) and syndromes, in order to reveal the disease and syndrome features of the population; Secondly, screening and identifying biomarkers for asthma and chronic obstructive pulmonary disease to provide a basis for precise prevention and treatment of the disease.",[353,354],"Asthma Bronchiale","Chronic Obstructive Pulmonary Disease (COPD)",[328,211,356,357,118],"Phenomics","Intelligent algorithms","2024-11-10",{"date":360,"type":36},"2024-11-12",{"date":362,"type":20},"2024-12-01",{"date":221,"type":20},{"name":42,"class":43},{"id":366,"slug":367,"hasResults":11,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":4,"eligibilityCriteria":371,"healthyVolunteers":11,"sex":16,"minAge":135,"maxAge":53,"enrollmentInfo":372,"targetDuration":4,"studyType":21,"phases":374,"briefSummary":375,"conditions":376,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":4},"100551098","effects-of-chinese-medicine-on-patients-with-severe-acute-exacerbation-of-copd-100551098","NCT06455670","Effects of Chinese Medicine on Patients With Severe Acute Exacerbation of COPD","Effects of Chinese Medicine on Patients With Severe Acute Exacerbation of COPD：A Multicentre, Randomised, Double-blind, Placebo-parallel Controlled Trial","Inclusion Criteria:\n\n1. Patients with severe AECOPD.;\n2. Age 40-80 years old;\n3. Chinese medicine diagnosis consistent with external cold and internal drink syndrome, or phlegm-heat congestion of the lungs syndrome, or phlegm turbidity obstruction of the lungs syndrome;\n4. Voluntarily accept the treatment and sign the informed consent form;\n\nExclusion Criteria:\n\n1. Pregnant and lactating women.\n2. delirious, dementia, various mental patients and other people who cannot communicate normally.\n3. Patients with severe cardiac insufficiency (NYHA grade IV), malignant arrhythmia and hemodynamic instability.\n4. Patients with acute respiratory failure who require tracheal intubation or invasive mechanical ventilation.\n5. Complicated with bronchiectasis, active tuberculosis, severe liver and kidney disease (severe liver disease refers to cirrhosis, portal hypertension and varicose vein bleeding, etc., serious kidney disease including dialysis, kidney transplantation, etc.), pneumonia, HIV infection or immunosuppressive state, advanced malignant tumor, etc.\n6. long-term bedridden patients for various reasons.\n7. Out-of-hospital treatment for more than 3 days.\n8. Participate in other drug clinical investigators within 1 month before enrollment.\n9. Allergic to therapeutic drugs.",{"count":373,"type":20},468,[23],"The purpose of this study was to evaluate the effects of Chinese Medicine on patients with severe AECOPD, and to provide a basis for the establishment of integrated CM and Western medicine diagnosis and treatment scheme for patients with severe AECOPD.",[377],"Acute Exacerbation Of Chronic Obstructive Pulmonary Disease","2024-10-18",{"date":380,"type":36},"2024-10-22",{"date":382,"type":20},"2024-10-20",{"date":384,"type":20},"2027-10-31",{"name":42,"class":43},{"id":387,"slug":388,"hasResults":11,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":4,"eligibilityCriteria":392,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":393,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":395,"conditions":396,"keywords":398,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":44},"100563245","cohort-study-on-the-treatment-of-severe-pneumonia-with-traditional-chinese-medicine-100563245","NCT06613659","Cohort Study on the Treatment of Severe Pneumonia with Traditional Chinese Medicine","Cohort Study on the Efficacy of Traditional Chinese Medicine Syndrome Differentiation Scheme in Adjuvant Treatment of Severe Pneumonia Based on the Real World","Inclusion Criteria:\n\n* It met the diagnostic criteria of severe pneumonia;\n* Age ≥ 18 years old, regardless of gender.\n* Voluntary treatment.\n* Sign the informed consent form.\n\nExclusion Criteria:\n\n* Pregnant or lactating women;\n* Patients with mental illness who are unable to cooperate or unwilling to cooperate with follow-up;\n* Those who are participating in clinical trials of other drugs;\n* Known allergic to therapeutic drugs.",{"count":394,"type":20},1016,"This is a multicenter, prospective cohort study, with syndrome differentiation and treatment of traditional Chinese medicine as the exposure factor. Patients using syndrome differentiation of traditional Chinese medicine combined with conventional treatment of Western medicine are classified as the treatment cohort of Integrated Chinese and Western medicine, and patients using conventional treatment of Western medicine only are classified as the treatment cohort of Western medicine",[397],"Community-Acquired Infections",[397,399,400],"Traditional Chinese Medicine","Cohort study","2024-09-25",{"date":403,"type":36},"2024-09-26",{"date":405,"type":20},"2024-09-20",{"date":407,"type":20},"2027-10-30",{"name":42,"class":43},{"id":410,"slug":411,"hasResults":11,"nctId":412,"briefTitle":413,"officialTitle":414,"acronym":4,"eligibilityCriteria":415,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":416,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":418,"conditions":419,"keywords":421,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":425,"startDateStruct":427,"completionDateStruct":429,"leadSponsor":430,"locationsCount":44},"100560481","respiratory-disease-cohort-studies-of-chinese-medicine-for-copdresearch-copd-100560481","NCT06577701","Respiratory Disease Cohort Studies of Chinese Medicine for COPD(RESEARCH-COPD)","Respiratory Disease Cohort Studies of Chinese Medicine for Chronic Obstructive Pulmoriary Disease (RESEARCH-COPD)","Inclusion Criteria:\n\n* Meets diagnostic criteria for chronic obstructive pulmonary disease (COPD) or preserved ratio impaired spirometry (PRISm).\n* Age ranges from 18 years to 80 years.\n* The investigators agreed to participate in this clinical study by voluntarily signing an informed consent form.\n\nExclusion Criteria:\n\n* Patients with delirium, dementia, various mental illnesses.\n* Pregnant and planned pregnant or lactating women.\n* Patients with other serious systemic diseases.\n* Patients who, in the opinion of the investigator, are not suitable for participation in this study.",{"count":417,"type":20},10000,"This study will establish a registration research platform, a clinical research database and a biospecimen bank for the prevention and treatment of COPD with Chinese medicine. Based on the COPD registry database, a cohort of Chinese medicine for COPD prevention and treatment will be established.",[327,420],"Preserved Ratio Impaired Spirometry (PRISM)",[327,420,422,399,423,400],"Complication (medicine)","Registration","2024-09-03",{"date":426,"type":36},"2024-09-19",{"date":428,"type":20},"2024-10-01",{"date":407,"type":20},{"name":42,"class":43},{"id":432,"slug":433,"hasResults":11,"nctId":434,"briefTitle":435,"officialTitle":436,"acronym":4,"eligibilityCriteria":437,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":438,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":439,"conditions":440,"keywords":442,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":450,"locationsCount":44},"100560485","respiratory-disease-cohort-studies-of-chinese-medicine-for-ild-research-ild-100560485","NCT06577753","REspiratory diSEAse cohoRt Studies of CHinese Medicine for ILD (RESEARCH-ILD)","REspiratory diSEAse cohoRt Studies of CHinese Medicine for Interstitial Lung Disease (RESEARCH-ILD)","Inclusion Criteria:\n\n1. Patients who meet the diagnosis of ILD;\n2. Age≥18 years old;\n3. Ability to provide independent informed consent.\n\nExclusion Criteria:\n\nPatients with acute ILD caused by known reasons, but the lesions disappear within 2 weeks after treatment. Example: Interstitial pneumonia caused by infections such as mycoplasma\u002Fvirus, and those who recover after treatment are excluded.",{"count":280,"type":20},"This study is a traditional Chinese medicine cohort for interstitial lung disease（ILD） in China, including at least 5000 patients with ILD and followed up for at least 5 years. The aim is to focus on the demographic characteristics, clinical features, disease occurrence and development characteristics, TCM syndrome evolution patterns, and clinical efficacy of TCM treatment for ILD in the real world.",[441],"Interstitial Lung Disease",[441,399,400],"2024-08-27",{"date":445,"type":36},"2024-08-29",{"date":447,"type":36},"2024-04-15",{"date":449,"type":20},"2030-12-30",{"name":42,"class":43},{"id":452,"slug":453,"hasResults":11,"nctId":454,"briefTitle":455,"officialTitle":456,"acronym":4,"eligibilityCriteria":457,"healthyVolunteers":156,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":458,"targetDuration":232,"studyType":111,"phases":4,"briefSummary":460,"conditions":461,"keywords":463,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":468,"startDateStruct":470,"completionDateStruct":472,"leadSponsor":474,"locationsCount":44},"100560154","exhaled-breath-condensate-biomarkers-in-caras-100560154","NCT06573450","Exhaled Breath Condensate Biomarkers in CARAS","Preliminary Application and Evaluation of Exhaled Breath Condensate Biomarkers in Combined Allergic Rhinitis and Asthma Syndrome (CARAS)","Inclusion Criteria:\n\n* Patients with AR, BA and CARAS who meet the Western medical diagnostic criteria;\n* Chinese medical evidence consistent with lung qi deficiency evidence, phlegm-heat congestion of the lung evidence, or wind-heat offending the lung evidence;\n* Age 18 to 80 years;\n* Voluntarily accepted the study and signed an informed consent form;\n* Not participated in other clinical studies within 1 month before enrollment.\n\nExclusion Criteria:\n\n* Patients with combined vasomotor rhinitis and eosinophilic non-allergic rhinitis, other non-allergic rhinitis diseases that can cause symptoms such as nasal congestion and runny nose;\n* Patients who are participating in other drug trials;\n* Patients with a combination of other serious systemic diseases;\n* Pregnant or lactating women;\n* Patients with confusion, disorders of consciousness, dementia, and various psychiatric disorders.",{"count":459,"type":20},270,"To explore the differences in the expression of biomarkers in different sample types between the healthy population and different subgroups of the disease, and to screen for potential biomarkers in a more simple, direct and objective way. To screen the biomarkers that can be identified by CARAS Chinese medicine symptoms and different stages, and to provide a reference basis for individualised diagnosis and treatment of the disease.",[462],"Combined Allergic Rhinitis and Asthma Syndrome",[464,465,466,467],"CARAS","EBC","Biomarkers","Combination of disease and evidence",{"date":469,"type":36},"2024-08-28",{"date":471,"type":36},"2023-04-01",{"date":473,"type":20},"2025-05-30",{"name":42,"class":43},{"id":476,"slug":477,"hasResults":11,"nctId":478,"briefTitle":479,"officialTitle":480,"acronym":4,"eligibilityCriteria":481,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":482,"targetDuration":4,"studyType":21,"phases":484,"briefSummary":485,"conditions":486,"keywords":488,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":493,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":498,"locationsCount":4},"100544971","bufei-recipe-reduces-the-incidence-rate-of-copd-100544971","NCT06375824","Bufei Recipe Reduces the Incidence Rate of COPD","Bufei Recipe Reduces the Incidence Rate of COPD: A Multicenter, Randomized, Double Blind, Placebo Controlled Study","Inclusion Criteria:\n\n1. Risk factors for chronic obstructive pulmonary disease. Having one item from a, b, and c (risk factors will be further optimized based on the screening results of high-risk populations):\n\n   1. smoking history (including previous and current smokers);\n   2. 1 year or more of exposure to dust or chemical toxins;\n   3. Indoor air pollution for 1 year or more (use of contaminated fuels, passive smoking, exposure) Oil fumes, etc.\n2. Have a history of chronic bronchitis and\u002For emphysema, and have one of the following chronic respiratory symptoms:\n\n   1. Cough (more than 3 months per year, continuous for 2 years or more);\n   2. Coughing phlegm (more than 3 months per year, continuous for 2 years or more);\n   3. Difficulty breathing (more than 3 months per year, continuous for 2 years or more).\n3. The lung function test meets the following criteria: forced expiratory volume in one second (FEV1)\u002Fforced vital capacity (FVC) ≥ 70% and FEV1 accounting for%\\\u003C80% of the expected value.\n4. Meets the diagnostic criteria for lung qi deficiency syndrome.\n5. Age range from 18 to 80 years old.\n6. Voluntarily participate in the study and sign an informed consent form.\n\nExclusion Criteria:\n\n* Pregnant and planned pregnancy, lactating women.\n* Dementia and various mental illness patients.\n* Other diseases with chronic cough, sputum production, or difficulty breathing.\n* Merge tumors.\n* Merge severe cardiovascular and cerebrovascular diseases.\n* Concomitant severe liver and kidney diseases.\n* Participants in clinical trials of other drugs.\n* Allergies to intervention drugs.",{"count":483,"type":20},1100,[23],"Establish early TCM prevention and treatment program to reduce the incidence rate of COPD.",[487],"Preserved Ratio Impaired Spirometry",[489,490,491],"Bufei Recipe","PRISm","incidence rate","2024-04-16",{"date":494,"type":36},"2024-04-19",{"date":496,"type":20},"2024-05-01",{"date":384,"type":20},{"name":42,"class":43},{"id":500,"slug":501,"hasResults":11,"nctId":502,"briefTitle":503,"officialTitle":503,"acronym":4,"eligibilityCriteria":504,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":505,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":507,"conditions":508,"keywords":509,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":514,"startDateStruct":516,"completionDateStruct":517,"leadSponsor":519,"locationsCount":44},"100544807","respiratory-disease-cohort-studies-of-chinese-medicine-for-asthma-research--asthma-100544807","NCT06373692","REspiratory diSEAse cohoRt Studies of CHinese Medicine for Asthma (RESEARCH- Asthma)","Inclusion Criteria:\n\n1. Patients who meet the diagnosis of bronchial asthma;\n2. Age 18\\~80 years old;\n3. Have not participated in other clinical studies within 1 month before enrollment;\n4. Voluntarily participate in the study and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Patients with respiratory failure and mechanical ventilation during acute asthma exacerbation;\n2. Delirium, impaired consciousness, dementia, and various mental illnesses;\n3. Patients with other lung diseases such as COPD, lung abscess, cystic fibrosis, bronchiectasis, etc., and severe liver and kidney diseases;\n4. Patients with neuromuscular diseases that affect respiratory motor function and are unable to complete the six-minute walk test;\n5. Pregnant and lactating patients;\n6. Those who are participating in other clinical trials.",{"count":506,"type":20},1508,"The purpose of this study is to define the standard use of TCM treatment regimen as the TCM cohort group and the non-TCM cohort group of those who use conventional Western medicine treatment without the standard TCM treatment regimen through a multi-center, large-sample prospective cohort study design. To evaluate the clinical efficacy and safety of TCM treatment regimens in the treatment of bronchial asthma, and to provide high-quality evidence for the promotion and application of TCM syndrome differentiation treatment in bronchial asthma.",[26],[510,511,512,513],"Bronchial asthma","Asthma control rate","Number of acute attacks","Cohort studies",{"date":515,"type":36},"2024-04-18",{"date":496,"type":20},{"date":518,"type":20},"2026-12-30",{"name":42,"class":43},{"id":521,"slug":522,"hasResults":11,"nctId":523,"briefTitle":524,"officialTitle":525,"acronym":4,"eligibilityCriteria":526,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":527,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":529,"conditions":530,"keywords":532,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":536,"startDateStruct":538,"completionDateStruct":539,"leadSponsor":540,"locationsCount":44},"100543010","screening-for-high-risk-chronic-obstructive-pulmonary-disease-100543010","NCT06350305","Screening for High-risk Chronic Obstructive Pulmonary Disease","Screening Study at High-risk Chronic Obstructive Pulmonary Disease","Inclusion Criteria:\n\n* According to the Diagnosis and Treatment Guidelines for Chronic Obstructive Pulmonary Disease (Revised in 2021), a multi-stage cluster random sampling method was used to select individuals from representative administrative villages with a history of chronic cough or sputum production, breathing difficulties, recurrent lower respiratory tract infections, and\u002For exposure to potential risk factors for chronic obstructive pulmonary disease.\n* The investigators agreed to participate in this clinical study by voluntarily signing an informed consent form.\n\nExclusion Criteria:\n\n* Patients who are delirious, have impaired consciousness, dementia, various psychiatric disorders, etc., and cannot be accurately informed of their basic physical condition.\n* Patients who, in the opinion of the investigator, are not suitable for participation in this study.",{"count":528,"type":20},3600,"This study is a multicenter cross-sectional study design aimed at screening risk factors for the combination of disease and syndrome in high-risk individuals with chronic obstructive pulmonary disease (COPD).",[531],"High-risk COPD",[533,534],"high-risk COPD","scale","2024-04-09",{"date":537,"type":36},"2024-04-11",{"date":496,"type":20},{"date":384,"type":20},{"name":42,"class":43},{"id":542,"slug":543,"hasResults":11,"nctId":544,"briefTitle":545,"officialTitle":546,"acronym":4,"eligibilityCriteria":547,"healthyVolunteers":11,"sex":16,"minAge":135,"maxAge":53,"enrollmentInfo":548,"targetDuration":4,"studyType":21,"phases":550,"briefSummary":551,"conditions":552,"keywords":553,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":558,"lastUpdatePostDateStruct":559,"startDateStruct":561,"completionDateStruct":563,"leadSponsor":565,"locationsCount":4},"100541192","bufei-yishen-prescription-on-patients-with-frequent-aecopd-in-stable-stage-100541192","NCT06326658","Bufei Yishen Prescription on Patients With Frequent AECOPD in Stable Stage","Evaluation of the Curative Effect and Health Economics of Bufei Yishen Prescription on Patients With Frequent Acute Exacerbation of COPD in Stable Stage","Inclusion Criteria:\n\n* Patients diagnosed with COPD at a stable stage.\n* Stable COPD patients with frequent acute exacerbation.\n* Age 40-80 years old.\n* The condition was stable 4 weeks before enrollment.\n* 5 did not participate in other drug clinical studies within 1 month before enrollment.\n* At least 3 months of maintenance therapy with triple inhalation preparation was used before enrollment.\n* Washout period was 2 weeks before enrollment.\n* Voluntarily receive treatment and sign informed consent.\n\nExclusion Criteria:\n\n* complicity with other diagnosed and clinically significant respiratory diseases, including but not limited to: asthma, active pulmonary tuberculosis, bronchiectasis, pulmonary hypertension, pulmonary embolism, pneumothorax, pleural effusion, interstitial lung disease, or other active pulmonary diseases requiring intervention.\n* Patients with severe or acute cardiovascular and cerebrovascular diseases (acute cardiovascular and cerebrovascular events, malignant arrhythmias, unstable angina pectoris, cardiac function grade 3 or above, uncontrolled hypertension, etc.).\n* Complicated with severe liver and kidney disease (severe liver disease refers to cirrhosis, portal hypertension and varicose vein bleeding, serious kidney disease including dialysis, kidney transplantation).\n* Any item of liver function index (ALT, AST) exceeds the upper limit of normal reference value by 1.5 times, and renal function index Scr exceeds the upper limit of normal reference value.\n* Tumor patients who have undergone surgical resection, radiotherapy and chemotherapy in the past five years.\n* Patients with mobility difficulties caused by severe osteoarthropathy, neuromuscular disease, and peripheral vascular disease.\n* Combined with absolute or relative prohibition of 6-minute walking test: such as resting heart rate \\> 120 beats\u002Fmin, systolic blood pressure \\> 180mmHg or diastolic blood pressure \\> 100mmHg; Or have limited activity to complete the 6-minute walking test.\n* Combined with cognitive or mental disorders.\n* Glucocorticoids were taken orally within 2 weeks before enrollment.\n* Had taken any Chinese medicine preparations (decoction, formula granule, proprietary Chinese medicine, etc.) prohibited during the study period according to the protocol within 2 weeks before enrollment.\n* People who are known to be allergic to therapeutic drugs.\n* Pregnant and lactating women, people who plan to become pregnant or cannot use effective contraceptive measures.",{"count":549,"type":20},848,[23],"To evaluate the clinical efficacy and health economic advantages of Lung Replenishing and Kidney Enhancing Formula for the treatment of patients with frequent acute exacerbations in the stabilized phase.",[211],[554,555,556,557],"Bufei Yishen Prescription","AECOPD","remission period","frequent","2024-03-17",{"date":560,"type":36},"2024-03-22",{"date":562,"type":20},"2024-04-01",{"date":564,"type":20},"2026-10-31",{"name":42,"class":43},""]